SOURCE: Daxor Corp.

February 22, 2007 08:30 ET

Daxor Announces Kaiser Permanente of Los Angeles, CA Acquires BVA-100 Blood Volume Analyzer

NEW YORK, NY -- (MARKET WIRE) -- February 22, 2007 -- Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from the Kaiser Permanente Los Angeles Medical Center, Los Angeles, California.

Kaiser Permanente is the largest nonprofit health plan in the United States, serving 8.2 million members in 9 states and the District of Columbia. Kaiser Permanente is an integrated health delivery system, which means that Kaiser Permanente provides and coordinates the entire scope of care for its members, including: preventative care, well-baby and prenatal care, immunizations, emergency care, screening diagnostics, hospital and medical services and pharmacy services. As a nonprofit health plan, Kaiser Permanente is driven by the needs of its members rather than the needs of shareholders. Kaiser Permanente's Los Angeles Medical Center is a 439-bed tertiary medical center.

Daxor's Blood Volume Analyzer BVA-100 will be located within the Los Angeles Medical Center's Nuclear Medicine Department, and will be utilized by cardiology and various critical care units to diagnose blood volume derangements in various medical and critical care conditions.

Dr. David Blumfield, Nuclear Cardiologist, said that, "A measured blood volume may be extremely helpful in diagnosing and then treating patients with a goal-directed measured value. Measured blood volumes will allow us to better utilize critical care beds and other expensive resources."

Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website www.Daxor.com.

Contact Information

  • Contact Information:
    Stephen Feldschuh
    Chief Operating Officer
    212-330-8515
    Email Contact

    Diane Meegan
    Investor Relations
    212-330-8512
    Email Contact.